Spots Global Cancer Trial Database for hepatocellular carcinoma by bclc stage
Every month we try and update this database with for hepatocellular carcinoma by bclc stage cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria | NCT05883176 | Hepatocellular ... | Bevacizumab Bio... | 18 Years - 70 Years | Sun Yat-sen University | |
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma | NCT03652896 | Hepatocellular ... | anatomical live... | 17 Years - 65 Years | Huazhong University of Science and Technology | |
Brazilian Reality of Hepatocellular Carcinoma | NCT06230328 | Hepatocellular ... Hepatocellular ... Hepatocellular ... Hepatocellular ... Hepatocellular ... | 18 Years - 100 Years | AstraZeneca | ||
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions | NCT05622071 | Hepatocellular ... | Tislelizumab | 18 Years - | UNICANCER | |
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization | NCT04780789 | Hepatocellular ... Hepatocellular ... | Transarterial C... | 18 Years - | Brno University Hospital | |
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization | NCT04780789 | Hepatocellular ... Hepatocellular ... | Transarterial C... | 18 Years - | Brno University Hospital | |
Brazilian Reality of Hepatocellular Carcinoma | NCT06230328 | Hepatocellular ... Hepatocellular ... Hepatocellular ... Hepatocellular ... Hepatocellular ... | 18 Years - 100 Years | AstraZeneca | ||
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma | NCT03652896 | Hepatocellular ... | anatomical live... | 17 Years - 65 Years | Huazhong University of Science and Technology |